#Japan #Tokyo #Depression #Lifton D #DT Axis

DT Axis Achieves Milestone in Depression Treatment

DT Axis, a prominent player in the mental health sector, has successfully obtained manufacturing and sales approval for its innovative depression treatment aid program, Lifton D®️. The approval, granted by the Ministry of Health, Labour and Welfare, marks a significant advancement in the company’s efforts to enhance mental health treatment options in Japan.

Background of Lifton D®️

Launched after years of research and development initiated in 2021, Lifton D®️ (Development Code: FHM-001) is Japan's first program dedicated to assisting patients battling moderate to severe depression, especially those whose symptoms persist despite receiving pharmacological treatments. The approval is designated as a Class II medical device, and this achievement is the first phase of a two-stage approval process. The second stage will include gathering additional clinical data to support its efficacy and safety in clinical settings.

The device was developed based on studies conducted by key researchers, Professor Koji Furukawa from Kyoto University and former Director Katsushi Horikoshi at the NCNP Center for Cognitive Behavioral Therapy. Together, they laid down the cognitive-behavioral models that drive Lifton D®️’s framework, focusing on alleviating specific psychiatric symptoms related to depression.

Efficacy of Lifton D®️

Research from exploratory clinical trials has shown promising results regarding Lifton D®️’s impact on patients. The trials utilized established measurement scales such as the Hamilton Depression Rating Scale (HAM-D) and Patient Health Questionnaire-9 (PHQ-9) to evaluate the program's effectiveness. Findings indicated notable trends in the relief of symptoms like depressed mood, feelings of guilt, anxiety, and somatic concerns, as per HAM-D results. Furthermore, PHQ-9 scores demonstrated significant improvements, suggesting that Lifton D®️ may offer a beneficial alternative or adjunct therapy for patients struggling with treatment-resistant depression.

DT Axis is currently preparing for the program's market entry while concurrently gathering necessary clinical evidence to apply for the second phase of approval, which will ensure comprehensive data regarding Lifton D®️'s effectiveness and safety in the real-world clinical environment.

Commitment to Mental Health Care

The vision for Lifton D®️ extends beyond just treatment approval; DT Axis aims to leverage digital technology through smartphone applications to provide innovative treatment options. By integrating Lifton D®️ into the mental health care infrastructure of Japan, DT Axis seeks to alleviate the burden associated with depression treatment and expand the array of clinical care choices available to healthcare professionals and patients alike. Their approach aligns with a broader initiative to improve patient care through accessible and effective mental health resources.

As the launch date approaches, DT Axis is dedicated to advancing mental health care, actively working to establish Lifton D®️ not only as a viable treatment option but also as part of a holistic approach to mental health management in Japan.

Important Notice

It is essential to emphasize that the information presented in this article and related press releases is not designed to promote products or serve as medical advice and should not replace consultation with healthcare providers. Lifton D®️ is a registered trademark of DT Axis Inc., and further details can be obtained directly through their official channels.

Conclusion

The approval of this groundbreaking program stands as a testament to DT Axis's commitment to transforming mental health treatment in Japan and represents hope for many individuals struggling with depression. Through continued research and development, Lifton D®️ could set a precedent for future innovations in psychiatric care.

[References available on Kyoto University press release]